Roth MKM Maintains Buy on Fortress Biotech, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Scott Henry has maintained a Buy rating on Fortress Biotech (NASDAQ:FBIO) but has reduced the price target from $30 to $15.
November 29, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Fortress Biotech's price target has been lowered from $30 to $15 by Roth MKM, although the Buy rating is maintained.
The reduction in price target by Roth MKM could lead to a negative perception among investors, potentially causing a short-term decline in FBIO's stock price. However, the maintenance of a Buy rating suggests underlying confidence in the company's fundamentals, which may mitigate some negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100